Q-omics provides the consensus-scored CYLC2 profile across patient tissues and cancer cell-line models. CYLC2 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, CYLC2 is differentially expressed in 2, with the highest sampling consensus in UCEC. Additionally, CYLC2 RNA expression shows 6,303 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUAD, UCEC, and STAD as cancer lineages where CYLC2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYLC2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYLC2 survival associations across molecular data types. CYLC2 RNA expression shows survival associations in the most cancer types (12), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYLC2 RNA expression–survival associations across cancer types. High CYLC2 expression shows unfavorable associations in LUAD, COAD, ACC, OV, KIRC and HNSC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for CYLC2 RNA expression.
This table summarizes CYLC2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for CYLC2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYLC2 shows higher tumor expression in UCEC and KIRP. The UCEC box plot shows higher CYLC2 RNA expression in tumor versus normal tissue (log2 FC = +0.065, t-test p = .049).
This table shows molecular features associated with CYLC2 in patient tissues and cancer cell lines. In patient samples, CYLC2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CYLC2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_NSCLC_LUAD.
